ISL
AZN icon

Ingalls & Snyder LLC’s AstraZeneca AZN Stock Holding History

Ingalls & Snyder LLC’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.6M Sell
29,529
-81
-0.3% -$15.2K 0.15% 101
2026
Q1 		$5.84M Buy
29,610
+844
+3% +$163K 0.21% 88
2025
Q4 		$5.29M Sell
28,766
-1,397
-5% -$245K 0.19% 85
2025
Q3 		$4.63M Sell
30,163
-135
-0.4% -$20.4K 0.15% 96
2025
Q2 		$4.23M Sell
30,298
-23
-0.1% -$3.22K 0.15% 105
2025
Q1 		$4.46M Sell
30,321
-487
-2% -$70.5K 0.15% 95
2024
Q4 		$4.04M Sell
30,808
-490
-2% -$68.6K 0.16% 105
2024
Q3 		$4.88M Sell
31,298
-227
-0.7% -$36.6K 0.19% 90
2024
Q2 		$4.92M Sell
31,525
-470
-1% -$70.7K 0.21% 83
2024
Q1 		$4.33M Sell
31,995
-72
-0.2% -$9.53K 0.19% 87
2023
Q4 		$4.32M Sell
32,067
-779
-2% -$101K 0.2% 88
2023
Q3 		$4.45M Buy
32,846
+1,454
+5% +$199K 0.21% 82
2023
Q2 		$4.49M Sell
31,392
-213
-0.7% -$31.3K 0.22% 79
2023
Q1 		$4.39M Sell
31,605
-247
-0.8% -$33.2K 0.23% 76
2022
Q4 		$4.32M Sell
31,852
-2,523
-7% -$316K 0.23% 73
2022
Q3 		$3.77M Sell
34,375
-85
-0.2% -$10.8K 0.21% 81
2022
Q2 		$4.55M Sell
34,460
-706
-2% -$92.6K 0.24% 73
2022
Q1 		$4.67M Sell
35,166
-1,970
-5% -$236K 0.21% 88
2021
Q4 		$4.33M Sell
37,136
-202
-0.5% -$23.8K 0.2% 94
2021
Q3 		$4.49M Buy
37,338
+21,151
+131% +$2.46M 0.21% 94
2021
Q2 		$1.94M Sell
16,187
-1,985
-11% -$218K 0.09% 168
2021
Q1 		$1.81M Sell
18,172
-143
-0.8% -$14.4K 0.08% 171
2020
Q4 		$1.83M Buy
+18,315
New +$1.94M 0.09% 161
2020
Q3 		– Sell
-12,290
Closed -$1.3M – 383
2020
Q2 		$1.3M Sell
12,290
-1,070
-8% -$111K 0.07% 173
2020
Q1 		$1.19M Buy
+13,360
New +$1.26M 0.08% 175
2019
Q4 		– Sell
-12,308
Closed -$1.1M – 416
2019
Q3 		$1.1M Sell
12,308
-25
-0.2% -$2.17K 0.05% 209
2019
Q2 		$1.02M Sell
12,333
-592
-5% -$46.4K 0.05% 222
2019
Q1 		$1.04M Hold
12,925
– – 0.05% 214
2018
Q4 		$982K Sell
12,925
-416
-3% -$32.5K 0.05% 207
2018
Q3 		$1.06M Buy
13,341
+1,000
+8% +$75.6K 0.04% 225
2018
Q2 		$867K Sell
12,341
-120
-1% -$8.63K 0.04% 220
2018
Q1 		$871K Hold
12,461
– – 0.04% 219
2017
Q4 		$865K Buy
+12,461
New +$840K 0.04% 226
2017
Q2 		– Sell
-12,266
Closed -$764K – 382
2017
Q1 		$764K Sell
12,266
-100
-0.8% -$5.82K 0.04% 221
2016
Q4 		$676K Buy
12,366
+642
+5% +$36.5K 0.04% 232
2016
Q3 		$770K Sell
11,724
-1,277
-10% -$83.5K 0.04% 214
2016
Q2 		$785K Buy
13,001
+300
+2% +$17.4K 0.05% 209
2016
Q1 		$715K Hold
12,701
– – 0.05% 197
2015
Q4 		$862K Buy
12,701
+430
+4% +$28.2K 0.06% 182
2015
Q3 		$780K Sell
12,271
-225
-2% -$14.8K 0.05% 183
2015
Q2 		$796K Sell
12,496
-250
-2% -$17.1K 0.04% 195
2015
Q1 		$872K Hold
12,746
– – 0.05% 190
2014
Q4 		$897K Sell
12,746
-350
-3% -$25.1K 0.05% 183
2014
Q3 		$935K Sell
13,096
-1,150
-8% -$84.2K 0.05% 182
2014
Q2 		$1.06M Sell
14,246
-3,300
-19% -$239K 0.05% 180
2014
Q1 		$1.14M Sell
17,546
-1,700
-9% -$110K 0.06% 172
2013
Q4 		$1.14M Buy
19,246
+160
+0.8% +$8.69K 0.06% 165
2013
Q3 		$991K Buy
19,086
+7,450
+64% +$374K 0.06% 173
2013
Q2 		$550K Buy
+11,636
New +$593K 0.04% 218

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ingalls & Snyder LLC's AZN Position: Q2 2026 in Review

Ingalls & Snyder LLC reduced its AstraZeneca (AZN) stake by 0.27% in Q2 2026, selling an estimated $15.2K and leaving 29,529 shares worth $5.6M. The position accounts for 0.15% of the portfolio, ranked #101.

Ingalls & Snyder LLC first reported a position in AZN in Q2 2013 and has held it in 49 quarters since. The position peaked at $5.84M in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Ingalls & Snyder LLC held 29,529 shares of AstraZeneca worth $5.6M as of Q2 2026.
  • Ingalls & Snyder LLC sold 81 AstraZeneca shares in Q2 2026, an estimated $15.2K.
  • AstraZeneca made up 0.15% of Ingalls & Snyder LLC's portfolio in Q2 2026, its #101 holding.
  • Ingalls & Snyder LLC first reported a position in AstraZeneca in Q2 2013 and has held it in 49 quarters since.
  • Ingalls & Snyder LLC's AstraZeneca position peaked at $5.84M in Q1 2026.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Ingalls & Snyder LLC's 13F filing for Q2 2026, filed 14 Aug 2026.